Abingworth closes Fund IV at $350m

The Anglo-American life sciences VC firm has exceeded the original $275m target for their Abingworth Bioventures IV fund (ABV IV), which was more than two times over-susbscribed.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.